Latest North America News

Mach7 Technologies reports a robust Q2 FY25 with a 15.6% increase in Contracted Annual Recurring Revenue, reaffirming its FY25 growth guidance and initiating a $5 million share buy-back.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

KALINA Power Limited has made significant strides in formalising its partnership with Crusoe Energy and is actively pursuing funding to support its 170 MW Power-CCS projects amid growing interest in Alberta's data centre market.

Industrial Minerals Ltd reports encouraging progress in its High Purity Quartz projects, including promising testwork results and strategic marketing efforts in China, supported by a recent $2.3 million capital raise.

EcoGraf Limited advances its vertically integrated battery anode materials business with a significant UFK loan mandate and progress across upstream, midstream, and downstream operations.

Bluechiip Limited reported a $221,000 net cash outflow for Q2 FY2025, with cash reserves dwindling to $121,000. The company has initiated a strategic review and plans a capital raise to secure its future.

American Rare Earths advances its Halleck Creek Project with record high-grade drilling results, a strategic collaboration with BMO Capital Markets, and a significant state grant, reinforcing its role in securing the U.S. rare earth supply chain.

Terra Uranium has significantly expanded its land holdings in the Athabasca Basin through strategic option agreements with ATHA Energy Corp, setting the stage for a robust 2025 drilling campaign amid a recovering uranium market.

Syrah Resources faced operational setbacks at its Balama graphite mine due to protests, prompting a force majeure declaration, yet it maintains a robust cash position and advances its downstream Vidalia anode material facility amid growing market demand.

Imagion Biosystems has secured a AU$3 million capital injection and resumed its collaboration with Siemens, setting the stage to prioritize FDA filings and advance its MagSense® HER2 breast cancer imaging program.

SciDev Ltd reports a seasonal revenue dip in Q2 FY25 due to US Oil & Gas sector uncertainty but marks a strategic milestone by securing its first PFAS treatment contracts in Europe.